On July 22, 2024, BIOVECTRA Inc. and Agilent Technologies, Inc. signed an agreement for Agilent, a global leader in life sciences, diagnostics and applied chemical markets, to acquire BIOVECTRA, a Canadian-based contract drug manufacturer, from H.I.G. Capital for approximately $1.3 billion (US$925 million).

BioVectra produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics, and supports early-stage clinical development to large-scale commercial manufacturing.

DLA Piper advised Agilent with a team led by partners Eric Wang and Philipp Tsukanov (both in Palo Alto) and Catherine Gibson (Vancouver) and included associates Jaspreet K. Mann (San Francisco), Kaleigh Nevin (Vancouver) and Gina Cassar (Palo Alto).